The D2 receptor (DRD2) is a binding site of many psychoactive drugs and it has been proposed as a genetic risk factor for psychiatric disorders. The aim of this investigation was to study the DRD2 S311C variant in major psychoses. We studied 1182 inpatients with diagnoses of bipolar disorder (n = 480), major depressive disorder (n = 269), schizophrenia (n = 366), delusional disorder (n = 44), psychotic disorder not otherwise specified (n = 23) and 267 healthy controls. Eight hundred and eighty-seven subjects were also scored for their lifetime symptomatology using the the Operational Criteria checklist for psychotic illness (OPCRIT). DRD2 variants were not associated with affected subjects even when possible confounders like gender and onset were considered. When we considered the 887 subjects with the symptomatologic analysis, we observed a significant association of the DRD2 S311C variant with both delusion and disorganization features. The association was present independently from diagnoses. Our results do not show that coding variants of the DRD2 S311C play a major role in conferring susceptibility to major psychoses, but they may be connected with disorganized and delusional symptomatology independently from diagnoses. Molecular Psychiatry (2000) The D2 receptor is the major binding site of many typical and atypical neuroleptic drugs and its gene has been cloned and mapped to 11q22-23.
Disturbances of dopamine transmission have been implicated in the pathogenesis of psychiatric disorders. Inhibitors of dopamine reuptake, like amineptine, have an antidepressant action; dopamine agonists, such as l-dopa, amphetamine or bromocriptine have psychotomimetic effects in schizophrenics. Conversely, neuroleptics have antipsychotic properties and can induce depression in affective patients through their blockade of D2 receptors. 1 The D2 receptor is the major binding site of many typical and atypical neuroleptic drugs and its gene has been cloned and mapped to 11q22-23. 2 Itokawa et al 3 reported a polymorphism causing a structural change from Serine to Cysteine at codon 311 of DRD2 (S311C); this substitution occurs in the third intracellular loop of the receptor. Preliminary results showed that DRD2 rarer TaqI variants were associated with higher levels of the monoamine metabolites homovanillic acid and 3-methoxy-4-hydroxyphenylglycol in lumbar cerebrospinal fluid in controls. 4 S311C has been proposed as a genetic risk factor for schizophrenia following the observation of an excess of S311C variants among schizophrenics. 5 Nevertheless a number of replications failed to confirm the initial report, [6] [7] [8] [9] [10] [11] [12] [13] [14] with only one replication in Caucasian schizophrenics. 15 Mood disorders have also been investigated. An increased density has been reported of D2 or D2-like receptors in the caudate of bipolar patients with psychotic symptoms, compared with both normal controls and nonpsychotic bipolar patients. 16 Moreover in the same chromosomal region a translocation has been observed cosegregating with bipolar disorder. 17 Knockout studies suggested a behavioral activity of DRD2. Balk et al 18 used homologous recombination to generate D2-receptor-deficient mice. Absence of D2 receptors led to animals that were akinetic and bradykinetic in behavioral tests and showed significantly reduced spontaneous movements. There is, therefore, the possibility that variants of the DRD2 receptor may elicit symptomatologic effects. Thus, it has been suggested that the influence of DRD2 variants should be analyzed more at the level of symptoms rather than syndromes. 19 Up to now both linkage and association studies failed to detect any association of DRD2 with mood disorders. [20] [21] [22] [23] [24] [25] [26] [27] [28] A small positive association was reported in a Spanish sample 29 but it failed to be replicated and a positive association was also found by Arinami et al, 19 but only when consider-ing mood disorder subjects with mood incongruent psychotic features. Traditionally the definition of the phenotype has been based on categorical diagnoses which do not guarantee biological homogeneity and have been considered reductive of the amount of information available from the whole symptomatologic presentation of patients. [30] [31] [32] Moreover, converging evidence indicates that susceptibility genes only elicit limited symptomatologic effects on psychiatric syndromes. [33] [34] [35] We have, therefore, developed a phenotype definition that is based on four symptomatological factors: Excitement, Depression, Delusion and Disorganization. 36 Our results are coherent with previous studies performed both in schizophrenia and mixed psychotic samples. [37] [38] [39] [40] [41] Family studies evidenced a moderate but significant heritability for all psychopathological factors. [42] [43] [44] [45] [46] [47] [48] The factors are stable over time 49 and they are correlated with regional anatomical abnormalities. 50 We have previously detected and replicated an association of the DRD2 S311C variant with disorganized symptomatology of schizophrenia. 51, 52 In the present study we investigated the possible influence of the DRD2 S311C polymorphisms in major psychoses.
For DRD2 S311C polymorphism, bipolars, major depressives, schizophrenics and delusionals did not show any overall genotypic association (Table 1) . When considering 2 × 2 tables a trend was observed toward an excess of DRD2 S311C among schizophrenics ( 2 = 4.29; df = 1; P = 0.038) as compared to controls. The association drops to non significance when corrected for multiple testing. Early age of onset (Ͻ25 years) and gender did not modify DRD2 variant frequencies significantly. Control subjects and patients in all diagnostic groups were in Hardy-Weinberg equilibrium.
When we considered the 887 subjects with the symptomatologic analysis, we observed a significant association of the DRD2 S311C variant with both delusion and disorganization features ( Table 2 ). The association was present independently from diagnoses and gender. Severity of illness is directly associated with symptom scores, and this could constitute a bias for the detection of liability factors. Then we repeated the calculation including clinical indicators of severity as covariants in turn. We considered the age of onset, current age and length of disease. None of those covariates significantly influenced the results (data not shown). The possible association of DRD2 with symptoms was suggested by the observation of Arinami et al 19 that the frequency of individuals with DRD2 variant was significantly higher in mood disorders with mood incongruent psychotic symptoms, but similar in mood disorders without psychotic features when compared with the controls. 19 Following this hypothesis, a symptomatologic analysis has been performed using SADS items on a small sample of schizophrenics and no association was detected. 53 We did not replicate the finding in a preliminary report using the DRD2 VNTR marker in a sample of 47 bipolar subjects. 54 However, we reported and confirmed an association of DRD2* S311C with disorganized symptomatology in a large sample of 267 schizophrenics and delusional subjects. 51, 52 This association may explain previous conflicting results where disorganized symptomatology was not considered and a variable rate of disorganized subjects may have influenced DRD2 frequencies.
In the present article we used a phenotype definition that is based on the lifetime excitement, depressive, delusional and disorganized symptomatology. 36 This is an alternative to the traditional use of psychiatric diagnoses to define the affected phenotype for genetic studies. 30, 31 However, the use of symptoms for phenotype definition may be considered a limitation as symptomatologic presentation may vary across illness episodes. We used a lifetime scoring perspective including ever-presented symptoms to reduce this bias, and follow-up studies evidenced that episodes are substantially stable over time. 55 We are currently collecting follow-up data to further reduce this bias.
Ethnic origin is also a cause of stratification bias but our sample was composed of subjects mainly collected in the North of Italy with Italian antecedents for at least two generations. Although genetic heterogeneity has been evidenced for some isolated populations (such as Sardinia, not included in our sample), Italy is characterized by a substantial genetic homogeneity. 56 Controls were screened for the absence of mental illnesses. Although this may introduce a bias on allelic frequencies, association studies comparing very common diseases like major depression should exclude these cases from the control sample, as they may obscure positive associations.
The use of drugs could bias our ability to detect naive symptomatology, but this should not constitute a major obstacle. 36, 57 Specifically, while most subjects were admitted assuming lithium, antidepressant or benzodiazepine treatments, we applied a lifetime perspective to rate the OPCRIT checklist, also using complementary sources of data like previous records and family informants. 58 This strategy allowed us to describe early drug-free illness phases.
Our sample is composed mainly of severe inpatients and this should indeed be considered a selection bias, probably due to the fact that our center is a tertiary care setting. On the other hand the selection of severe subjects should guarantee against the possible inclusion of phenocopies; in fact it has been proposed to exclude less severe forms of mood disorders like single episode major depression as they are considered to have less genetic contribution. 32 In conclusion, DRD2 S311C variant was not a major liability factor for the development of major psychoses, but it may be connected with the disorganized and delusional symptomatology independently from diagnoses.
Methods

Sample
One thousand one hundred and eighty-two inpatients (age = 44.70 ± 14.35 years; onset = 30.20 ± 12.19 years; males 44%) consecutively admitted to the Department of Psychiatry at the Institute H San Raffaele were included in this study. Two hundred and sixty-seven subjects were included in previous papers reporting an association with psychotic symptomatology. 51, 52 One hundred and ninety-nine patients considered for this study were part of the sample collected for the European Collaborative Project on Affective Disorders, 59 but they have not been typed for DRD2 S311C variants for the consortium. Lifetime diagnoses were assigned by two independent psychiatrists on the basis of clinical interviews and medical records, according to DSM-IV criteria following a best estimate method. 58 A subsample of 887 patients was evaluated using the OPCRIT checklist with a lifetime perspective. 60 Criteria for inclusion in the study were diagnosis of major psychoses. The presence of concomitant diagnoses of mental retardation or drug dependence, somatic or neurological illnesses that impaired psychiatric evaluation represented exclusion criteria.
Two-hundred and sixty-seven control subjects were recruited among both healthy department personnel and people attending the general lab of our hospital (age = 46.62 ± 15.93; males 48%). Before drawing blood samples, controls were closely investigated to determine whether they or their first-degree relatives had psychiatric disturbances or previous psychiatric treatment, through interviews with subjects and relatives when possible. Only unaffected subjects with negative family histories were included in the study. It should be noted that those data were not collected through the detailed methodology used in family studies, and that a substantial rate of false negatives is commonly observed. 61 Informed consent was obtained from all subjects; these were unrelated and of Italian descent, with antecedents from all parts of the country.
DNA analysis
Genomic DNA was extracted from anticoagulated thawed blood according to the method of Lahiri and Nurnberger. 62 PCR-based genotyping of Ser311/Cys311 variant was carried out according to the method described by Arinami et al. 5 PCR products were digested with Sau961 restriction enzyme (New England Biolabs). The digested PCR products were resolved in 3.5% agarose gel by electrophoresis, and visualized with ethidium bromide staining by ultraviolet light. The Ser311 allele shows bands of 126 bp, 92 bp, 53 bp and 23 bp, whereas the Cys311 allele shows bands of 149 bp, 92 bp and 53 bp. Genotyping has been checked by two readers who were blind to clinical data.
Statistical analysis
The factoring process of the OPCRIT checklist has been previously presented. 36 . Factor scores were calculated as the sum of binarized items divided by the number of items in each factor. They were considered to be dependent variables when investigating their distribution across variants. Differences of factor scores among variants were assessed using one-way Analysis of Variance (ANOVA). Analysis of Covariance (ANCOVA) was used when including covariates. Alpha values were considered significant when below 0.01 (Bonferroni corrected: 0.05 divided by five factors). The power of our sample to detect differences amongst DRD2 variants was calculated considering an alpha value of 0.01, two-tailed. With these parameters in our sample we had a high power (0.80) to detect a medium effect size (0. 49) , that corresponded to a difference of approximately 0.12 points between the two DRD2 variants on factor scores. 64 Data were analyzed with a Chi-square test for the overall association with diagnoses; 2 × 2 tables composed by Ser311/Cys311 vs Ser311/Cys311 were used.
